VBI Vaccines receives grant to advance RSV candidate

VBI vaccines receives funds for for RSV vaccine’s eVLP Platform
VBI vaccines receives funds for for RSV vaccine’s eVLP Platform | Courtesy of
VBI Vaccines Inc. recently received approximately $265,000 in grants to further develop the company’s eVLP Platform, which will be used to create a respiratory syncytial virus (RSV) vaccine candidate.

RSV, a virus, infects the airways and lungs and can result in serious illness in both infants and elderly adults. The Centers for Disease Control and Prevention (CDC) have stated that nearly all children contract an RSV infection by 2 years old. Between 25 percent and 40 percent of these children manifest symptoms of bronchiolitis or pneumonia, and 2 percent need hospitalization.

The funds were granted from the National Research Council – Industrial Research Assistance Program (NRC-IRAP), a Canadian organization that receives sponsorship from the government. It offers business and technical advisory services and financial support for the creation and sale of novel technologies developed within Canada.

"Recent research suggests that the shape, or conformation, of the target proteins in an RSV vaccine may influence the potency and success of the candidate," David Anderson, VBI's senior vice president of research, said. "We are optimistic that by applying our eVLP Platform technology to RSV, we may contribute to the advancement of an improved RSV vaccine candidate. We are grateful to NRC-IRAP for their support in helping us advance this important research."

Organizations in this Story

VBI Vaccines Inc

Want to get notified whenever we write about VBI Vaccines Inc ?
Next time we write about VBI Vaccines Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.